Get ready for a slew of diabetes news announcements, because the ADA’s huge annual conference starts today!
I’ll be on an airplane pretty much all day (Friday) heading out to Orlando to cover this conference live, although I must warn you: it’s quite overwhelming. Running around the 450,000 square-foot convention center trying to see every diabetes company represented in the enormous exhibit halls while hundreds of symposia and other talk sessions are happening simultaneously is…
Read more »
Novo Nordisk is well-known in the diabetes community for its insulins, Novolog and Levemir, used to treat mainly type 1 diabetes. But in the last year, Novo launched a new kind of injectable, a “first line of defense for people with type 2 diabetes” called Victoza (generic: liraglutide). It’s a glucagon-like peptide-1 (GLP-1) drug designed to stimulate insulin secretion when hyperglycemia (high blood sugar) is present.
Victoza is still the new kid on the block…
Read more »
By
AmyT on
March 31, 2009
What is the biggest problem with treating Type 1 diabetes? The experts all say it’s that the insulins we have to inject simply aren’t fast enough; they don’t really mimic the effect of natural pancreas delivery because they take too long to kick in.
Several companies are rushing to solve this problem with the obvious: super-fast-acting insulin analogs, such as the relatively new Glulisine (aka Apidra), and BioDel’s ViaJect, currently being submitted for FDA review.…
Read more »
By
AmyT on
December 11, 2008
There are a lot of things going on at the troubled Food and Drug Administration right now that could have a profound impact on the future of diabetes care, but most of us patients never hear about them. And that’s a damn shame. Because we stand at a crossroads.
You may or may not be aware that the Obama Administration is about to appoint a new FDA Commissioner. The politics and personal leanings of this…
Read more »
